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Colorectal cancer (CRC) progression and eventually metastasis is directed in many aspects
by a circuitous ecosystem consisting of an extracellular matrix scaffold populated by
cancer-associated fibroblasts (CAFs), endothelial cells, and diverse immune cells. CAFs
are recruited from local tissue-resident fibroblasts or pericryptal fibroblasts and distant
fibroblast precursors. CAFs are highly abundant in CRC. In this review, we apply the
metastasis-promoting communication of colorectal CAFs to 10 cancer hallmarks described
by Hanahan and Weinberg. CAFs influence innate and adaptive tumor immune responses.
Using datasets from previously published work, we re-explore the potential messages
implicated in this process. Fibroblasts present in metastasis (metastasis-associated fibrob-
lasts) from CRC may have other characteristics and functional roles than CAFs in the
primary tumor. Since CAFs connect metastasis-promoting communication, CAF markers
are potential prognostic biomarkers. CAFs and their products are possible targets for novel
therapeutic strategies.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and a
major cause of mortality in the western society. The 5-year survival
rate is approximately 66.1% for all stages (1). However, prognosis
is strongly related to stage at diagnosis. The 5-year relative survival
rates are 90% for localized disease compared with 13% for patients
with distant metastases at diagnosis (2). The major cause of death
in this malignancy is development of metastases in liver and lung.
The majority of patients with metastatic CRC remain incurable
and currently have a median survival of 2 years (3).
In the past decades, treatment and molecular characteristics
relating to prognosis of CRC were mainly focused on the malig-
nant cancer cells. However, recent studies revealed that CRC pro-
gression is directed in many aspects by a circuitous ecosystem
consisting of an extracellular matrix (ECM) scaffold populated
by cancer-associated fibroblasts (CAFs), vascular space-related
cells (endothelial cells, pericytes, and smooth-muscle cells), and
diverse innate and adaptive immune response cells (lymphocytes,
macrophages, and mast cells) (4). In this review, we discuss the
role of CAFs in CRC and their tumor-promoting characteristics
on the basis of the 10 hallmarks of cancer of Hanahan and Wein-
berg (5). To better understand the role of CAFs in CRC, we first
explore the role of resident fibroblasts under healthy physiological
circumstances in the colon. Despite the evidence of the role of
CAFs in tumor progression, we explore the possibility that CAFs
may have tumor-inhibiting effects as well. Finally, we discuss the
role of fibroblasts in metastases of CRC.
FIBROBLASTS IN THE NORMAL COLON
In the normal colon, fibroblasts are spread throughout the lam-
ina propria adjacent to the colon mucosal epithelium. These
fibroblasts are in a resting state and are α-smooth-muscle actin
(α-SMA) negative (6). Pericryptal fibroblasts (PCFs) express α-
SMA, smooth-muscle myosin, vimentin, and are desmin-negative,
defining them as myofibroblasts (7). These are mesenchymal cells
that express features of fibroblast and smooth-muscle differenti-
ation (8). PCFs are located subjacent to the crypt epithelial cells
and follow the contours of the wall of the crypt (9). This enables
PCFs to establish and maintain instructive communications with
colonic stem cells and their descendants (10). PCFs maintain a
parallel relationship in replication, differentiation, and migration
with the overlying epithelium (9). The interaction between these
cells helps to maintain tissue integrity (11). PCFs deposit type IV
collagen necessary for the production of the pericryptal basement
membrane (6). PCFs are important for epithelial differentiation
during fetal and adult life and for the absorptive function of the
crypts, interacting with epithelial cells through a paracrine mecha-
nism by transforming growth factor-β (TGF-β), interleukin (IL)-6,
and leukemia inhibitory factor (LIF) (12). Furthermore, PCFs are
implicated in the regulation of mucosal inflammation. Through
their secretion of cytokines, chemokines, eicosanoids, and ECM
components, stromal cells affect the recruitment, retention, and
activation of immune cells. PCFs exhibit class II major histo-
compatibility complex expression and are strategically located
at the interface between the epithelium and lymphocytes of the
lamina propria. Therefore, PCFs may be among the first cells
to interact with antigens that cross the epithelial barrier and
present them to lamina propria CD4+ T-cells, which initiate and
maintain adaptive immunity (8). In the colonic mucosa, there
are three major populations of mesenchymal cells: PCFs, lamina
propria fibroblasts, and smooth-muscle cells of the muscularis
mucosae. These cell populations are interconnected, forming a
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complex three-dimensional scaffold. PCFs connect to the cells
of the muscularis mucosae at the base of the crypts, whereas
they also form a syncytium with the lamina propria fibrob-
lasts, which is in turn linked with the pericytes of the mucosal
capillaries (7).
FIBROBLASTS IN CRC
COLON CAFs
Fibroblasts of the tumor stroma are called activated fibroblasts,
myofibroblasts, tumor-associated fibroblasts, or CAFs. They are
the main cellular constituents of stroma associated with primary
and metastatic CRC (4, 13). Commonly used markers to iden-
tify CAFs are α-SMA, fibroblast activation protein-α (FAP-α),
fibroblast-specific protein-1 (FSP-1/S100A4), or platelet-derived
growth factor receptor-β (PDGFR-β) (14). Individually, these
markers could identify specific subpopulations of fibroblasts, thus
it would be more correct to use a combination of markers to
select the largest possible population of CAFs (15). α-SMA has
been demonstrated not to label CAFs exclusively, but also smooth-
muscle cells in the muscularis mucosae and muscularis propria
(16, 17). FAP appears to be expressed on pericytes and CAFs
(17). Quiescent resident fibroblasts express vimentin, instead of
α-SMA, as intermediate filament proteins (18). CAFs are negative
for smooth-muscle markers smoothelin and desmin and positive
for the marker CD90, which is not expressed in T-lymphocytes
in human (8). CAF cultures maintain the phenotypic charac-
teristics of CAFs even in absence of interaction with cancer
cells (4).
The number of myofibroblasts is strongly increased in CRC
compared to normal mucosa. It was demonstrated that lamina
propria fibroblasts change from α-SMA− to α-SMA+ in colorectal
polyps, suggesting that interstitial lamina propria fibroblasts show
myofibroblast differentiation (7). Accordingly, genes up-regulated
in the tumor stroma versus normal stroma encompassed CAF
markers, such as PDGFR-β or FAP (14).
The origin of CAFs is diverse and still under investigation.
The majority of CAFs are generated by differentiation of resi-
dent fibroblasts. It is suggested that cancer cells recruit fibroblasts
and secrete factors that promote their myofibroblast differentia-
tion, as part of prominent fibrosis known as tumor desmoplasia
(19). Desmoplasia consists of CAFs as key cellular component and
is a pathologic feature of human solid cancers and their metas-
tases (13, 20). Several cytokines including TGF-β, platelet-derived
growth factor (PDGF), IL-4, IL-6, insulin-like growth factor (IGF)-
II, and prostaglandin E (PGE) have been reported to induce CAF
differentiation (3, 21–23). A second source of CAFs are mesenchy-
mal stem cells (MSCs) residing in the bone marrow. MSCs are
multipotent non-hematopoietic cells that can differentiate into
different types of mesenchymal cells (21). MSCs were shown to be
attracted to the tumor microenvironment, where they proliferate
and become CAFs (17). Differential secretome profiling between
CAFs from CRC compared to bone marrow-derived MSCs (BM-
MSCs) demonstrated that 52.5% of proteins were detected in both
samples. It has been revealed that treatment of BM-MSCs with
recombinant TGF-β1 induced a CAF-phenotype with increased
α-SMA expression, stress fiber organization, and loss of multipo-
tency (24). Recombinant TGF-β1 induced secretion of 84 proteins
in MSCs, of which 16 proteins were also present in the CAF secre-
tome. This indicates that additional factors probably act in cooper-
ation with TGF-β1 to induce a fully differentiated MSC phenotype
or suggests several precursors of CAFs (24). Indeed, experimental
data propose a number of other cell types that may be a source
of CAFs, including adipocytes, stellate cells, pericytes, circulat-
ing mesenchymal or hematopoietic stem cells, and CD34-positive
fibrocytes (3,23). CAF differentiation is stimulated by reactive oxy-
gen species (ROS), acting through both TGF-β1-dependent and
-independent mechanisms. Less is known about factors inhibit-
ing CAF differentiation. The inflammatory cytokines interferon
(IFN)-γ and tumor necrosis factor (TNF)-α inhibit differentia-
tion (3). One of the CAF recruitment mechanisms by cancer cells
is increased expression of tissue inhibitors of metalloproteinases
(TIMP)-1. Stroma of human prostate and colon cancer expresses
higher levels of TIMP-1 compared to its phenotypically normal
counterpart. TIMP-1 leads to increased CAF proliferation and
migration through binding of TIMP-1 to its receptor CD63, which
is expressed on CAFs (25).
TUMOR-PROMOTING CHARACTERISTICS OF CAFs
In 2000, Hanahan and Weinberg identified six hallmarks of cancer,
primarily focusing on the phenotypic changes required for nor-
mal tissue to become cancerous. A decade later new insights led
to two emerging hallmarks (reprograming of energy metabolism
and evading immune destruction) and two new enabling charac-
teristics (tumor-promoting inflammation and genome instability
and mutation) (5). Many of these hallmarks are interconnected
and the role of CAFs is described below (Figure 1).
Sustaining proliferative signaling, resisting cell death, and evading
growth suppressors
Multiple CAF-derived factors sustain proliferative signaling in
CRC cells and support the cancer cells to resist cell death and evade
FIGURE 1 | Hallmarks of cancer regulated by CAFs after Hanahan and
Weinberg (5).
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growth suppressors. Colon CAFs secrete epidermal growth factor
(EGF), hepatocyte growth factor (HGF), IGF1/2, PGE-2, PDGF,
fibroblast growth factor (FGF)-1, and vascular endothelial growth
factor (VEGF) (20, 21, 24). These growth factors act through acti-
vation of the mitogen-activated protein kinase (MAPK) and phos-
phatidylinositol 3-kinase (PI3K)/AKT pathways, which mediate
cell proliferation and cell survival (anti-apoptotic signaling), pro-
tein synthesis, cytoskeletal rearrangements, and invasion (26). For
example, it was demonstrated that HGF and neuregulin-1 in super-
natants of CAFs were able to phosphorylate the receptor tyrosine
kinase c-Met and human epidermal growth factor receptor (HER)-
2/HER-3 in CRC cells thereby activating both the MAPK and
PI3K/AKT pathway. Consequently, supernatants of CAFs induced
an increase in CRC cell counts and tumorigenicity (27, 28).
CAF-derived TGF-β and connective tissue growth factor
(CTGF) leads to proliferation through the Smad2/Smad4 pathway
(20, 21, 24, 29). The interaction of cancer cells with CAF-derived
factors initiates TGF-β signaling and growth in CRC cells with a
functional TGF-β receptor complex, possibly through activation
of latent TGF-β1 (22). The putative TGF-β-target IGFBP-7 was up-
regulated in CAFs compared to normal resting colonic fibroblasts.
Although IGFBP-7 is a known tumor suppressor, CAFs express-
ing IGFBP-7 stimulate colony formation of co-cultured CRC cells,
suggesting that IGFBP-7 indirectly promotes tumor progression
through manipulation of CAFs (14).
The ECM protein periostin is secreted by PCFs and CAFs in the
colon. Both colony size and number of HCT116 cells were signif-
icantly larger when cultured with periostin-producing fibroblasts
than with non-producing ones in a three-dimensional co-culture
system (12). Epiregulin expression is up-regulated in patients with
colitis-associated cancer. CAFs were identified as major source.
CAF-derived epiregulin requires ERK activation to induce prolif-
eration of CRC cells and tumor development in vivo (30). CD133+
CRC cells exhibit enhanced tumorigenicity over CD133− cells.
Up-regulated genes in CD133+ cells included chemokine receptor
CXCR4, integrinβ8,and fibroblast growth factor receptor (FGFR)-
2. The adjacent CAFs overexpress the gene transcripts for the
activating ligands: stromal-derived factor-1 [SDF-1; also known
as C–X–C motif ligand 12 (CXCL-12)], macrophage migration
inhibitory factor (MIF), vitronectin, and FGF family members. In
matrigel three-dimensional culture, the CD133+/CXCR4+ group
treated with recombinant SDF-1 led to more and larger colonies
compared with vehicle. CD133+ cells are spatially located next to
a relative abundance of CAFs in CRC. Thus, the enhanced tumori-
genic potential of CD133+ cells possibly origins in their increased
ability to interact with their neighboring CAFs (31).
Two prototypical tumor/growth suppressors are the retinoblas-
toma (RB)-associated and TP53 proteins. The p53 gene (TP53)
encodes a transcription factor that acts as a tumor suppressor and
can be activated in response to oncogenic stress signals. Once acti-
vated, p53 induces apoptosis or replicative senescence in order
to prevent the proliferation of potentially malignant cells. p53
induction alters CAFs’ protein secretion, leading to a less support-
ive microenvironment. For instance, p53 can repress the expres-
sion of the chemokine SDF-1 in fibroblasts. In agreement with a
tumor suppressor role for p53 in CAFs, lung cancer cells suppress
p53 induction in CAFs, by a mechanism that is independent of
direct cell–cell contacts. Human CAFs are more susceptible to this
inhibitory mechanism than their normal counterparts (32). The
RB protein is hypo-phosphorylated in quiescent or differentiated
cells, it interacts with E2F family transcription factors, repress-
ing the transcription of genes essential for cell cycle progression.
In isolated breast CAFs, RB protein is inactivated by phosphory-
lation, consistent with cell cycle progression (33). In accordance,
oro-pharyngeal cancer specimens were analyzed by immunohisto-
chemical staining for phosphorylated RB protein, demonstrating
that RB and RB-dependent pathways were generally inactivated
in CAFs. Depletion of RB in CAFs enhances the invasive poten-
tial of cancer cells through increased production of CAF-derived
keratinocyte growth factor (KGF or FGF7), that regulates invasion
via an AKT–Ets2–matrix metalloproteinase (MMP)-1-dependent
pathway (34). Further studies are necessary to conclude about the
role of p53 or RB in colon CAFs.
Deregulating cellular energetics and genome instability and
mutation
The role of CAFs in deregulating cellular energetics has been
reviewed by Martinez-Outschoorn et al. (35). Metabolic connec-
tion occurs between catabolic fibroblasts and anabolic cancer cells.
In brief, altered cell signaling pathways in cancer cells drive the gen-
eration of ROS and autophagy in adjacent CAFs. In turn, catabolic
CAFs fuel tumor growth through energy and biomass transfer
to anabolic cancer cells. CAF catabolism is associated with poor
clinical outcome (35).
Immunohistochemical evaluation of colorectal adenocarcino-
mas revealed a reduced pyruvate dehydrogenase (PDH) expression
and a high lactate dehydrogenase-5 (LDH-5) isoenzyme and PDH-
kinase1 (PDK1) reactivity in CRC cells (36). PDK1 is an enzyme
inhibiting PDH activity. Thus, cancer cells are directed to anaero-
bic glycolysis for energy, which is mediated by pyruvate transfor-
mation to lactic acid via the catalytic activity of LDH-5. Cellular
metabolism shifts to anaerobic pathways for ATP production when
there is only suboptimal oxygen availability. However, cancer cells
show an intrinsic trend to switch to glycolysis even in the presence
of high oxygen, the so-called Warburg effect. In contrast, CAFs
maintain a rather strong PDH expression whereas reduced LDH-5
and PDK1 activity is noticed. This indicates metabolism pro-
ceeding to pyruvate followed by oxidative phosphorylation in the
mitochondria. CAFs demonstrate a widespread localization of the
LDH-1 isoenzyme, which has reduced ability to convert pyruvate
to lactate compared with LDH-5, thereby promoting oxidation of
lactate back to pyruvate. The stroma forms a major buffer of acid-
ity through the absorption of lactic acid released by CRC cells and
recycling it back to pyruvate, sustaining cancer cell survival (36).
CRC cells close to CAFs have a high proliferative index, high HIF-
1a and LDH-5 reactivity, and a tendency to extramural extension.
Lactate increases intracellular oxidants, promoting proliferation
of cultured fibroblasts (37). CAFs express proteins involved in lac-
tate absorption, lactate oxidation, and reduced glucose absorption.
Therefore, CAFs use lactate for energy and save glucose for can-
cer cells, which are dependent upon anaerobic metabolism with a
high ability for glucose absorption. In conclusion, the complemen-
tary metabolic function of cancer cells and CAFs shows synergistic
support to each other (36).
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Metabolic coupling and mutagenic co-evolution of epithelial
cancer cells and CAFs during tumor formation was demonstrated
in a co-culture of normal human fibroblasts with MCF-7 breast
cancer cells. Breast cancer cells induce ROS production and a loss
of caveolin-1 in adjacent fibroblasts, leading to a CAF-phenotype.
The loss of caveolin-1 in fibroblasts triggers nitric oxide (NO) pro-
duction, mitochondrial dysfunction, and oxidative stress via ROS
production. Oxidative stress promotes DNA damage and genetic
instability in cancer cells, potentially increasing their aggressive
behavior (mutagenic evolution) by a bystander effect (38). Sim-
ilarly, CRC cells can acquire genetic alterations by an oxidative
stress induced bystander effect. It was demonstrated that infection
by Enterococcus faecalis, a constituent of the intestinal microbiota
known to generate ROS, induced genetic instability and aneu-
ploidy in colonic epithelial cells (39). On the other hand, oxidative
stress due to loss of caveolin-1 triggers aerobic glycolysis in breast
CAFs, which is in contrast to the results obtained in CRC. Accord-
ing to “The Reverse Warburg Effect,” cancer cells and stromal
fibroblasts dynamically co-evolve and become metabolically cou-
pled during tumor formation, inducing aerobic glycolysis in CAFs
by cancer cells. As a consequence, these CAFs secrete high levels
of energy-rich metabolites (such as lactate and pyruvate) that are
directly absorbed by tumor cells and used for efficient ATP pro-
duction via oxidative phosphorylation (38). However, these data
remain limited to CAFs activated by deletion/down-regulation of
caveolin-1 and are not reported for CRC.
Inducing angiogenesis
Colon CAFs produce significant amounts of IL-6 and CRC cells
further enhance IL-6 production by CAFs. IL-6 is a multifunc-
tional cytokine that plays a central role in the regulation of inflam-
matory and immune responses, but it is also characterized as an
angiogenic cytokine. RT-PCR and ELISA demonstrated that IL-6
up-regulated the expression of VEGFA mRNA and VEGFA protein
from both normal colon fibroblasts and CAFs. IL-6 was suggested
to stimulate VEGF secretion by the mediation of PGE-2 from
CAFs. Secreted VEGF from fibroblasts targets endothelial cells
and is known as one of the most important angiogenic factors. Co-
cultures of colon fibroblasts and human umbilical vein endothelial
cells were used as an angiogenesis model. Immunostaining with
anti-CD63 antibody showed increased vascular area and vascular
network formation after treatment with recombinant IL-6 (40).
Co-cultures of CRC cells with CAFs revealed a synergistic increase
of VEGF production compared with monocultures. The expres-
sion of VEGF mRNA in CAFs was significantly increased by co-
culture with CRC cells, suggesting that the large amounts of VEGF
detected in the supernatants of co-cultures were mainly derived
from CAFs (41). Follistatin-like protein-1 (FSTL-1) expression
was observed in the human CRC stromal compartment. FSTL-
1 is a TGF-β-inducible gene, secreted protein and acidic and
rich in cysteine (SPARC)-related, that enhances inflammatory
cytokine/chemokine expression and also seems to be implicated
in angiogenesis and revascularization (29).
To examine which other proteins secreted by CAFs are impor-
tant for angiogenesis, we analyzed data of De Boeck et al. Proteins
secreted by CAFs, MSCs, or recombinant TGF-β1-treated MSCs
were reported (24). We specifically studied the proteins uniquely
secreted by CAFs and by the combination of CAFs and recombi-
nant TGF-β1-treated MSCs, which are not secreted by non-treated
MSCs. Re-analysis of these proteins through the functional enrich-
ment analysis tool (FunRich – http://www.funrich.org/) revealed
that 19.44% is implicated in angiogenesis (Table 1).
CAF-derived chemokine SDF-1 (CXCL-12) is reported to
recruit endothelial progenitor cells into breast carcinomas to
induce angiogenesis. Breast cancer cells mixed with CAFs in a
xenograft model led to highly vascularized tumors (42). IFN-γ
has immunomodulatory and other anti-tumor activities. Selective
targeting of IFN-γ to CAFs and pericytes through a PDGFβR-
binding carrier, because these cells express high levels of PDGFβR,
reduces tumor growth by inhibition of angiogenesis. In mice sub-
cutaneously injected with B16-F10 melanoma cells, α-SMA+ cells
(fibroblasts and pericytes) were reduced in targeted IFN-γ-treated
tumors. CD31 staining of the lumen area of tumor blood vessels
demonstrated a significant reduction in angiogenesis (43). IL-6
and FSTL-1 are not present in the FunRich results, because these
proteins are also secreted by non-treated MSCs, but their secretion
is increased in CRC (24).
TIMP-1 is a prognostic marker in plasma from CRC patients.
Higher levels of TIMP-1 were present in patients with metastases.
In liver metastases, TIMP-1 was expressed by α-SMA+-activated
hepatic stellate cells (HSCs) situated adjacent to CD34-positive
endothelial cells, suggesting a function in tumor-induced angio-
genesis (44). In an orthotopic nude mice model, KM12SM human
CRC cells mixed with MSCs were injected into the cecal wall. CD31
staining of the primary tumor demonstrated that the microvessel
area was significantly greater in the KM12SM+MSCs group than
in the KM12SM-alone group. When mice were treated with ima-
tinib, which is a tyrosine kinase inhibitor of PDGFR, there was no
difference anymore between the two groups (45, 46).
Table 1 | Angiogenesis-related proteins secreted uniquely by CAFs
from CRC and by the combination of CAFs and recombinant
TGF-β1-treated MSCs according to their category.
Cytokine/chemokine
activity
Growth factor Others
GDF-15 EGF PPP2CA
TGFB-2 HGF PPP2R1A
CCL-5 FGF-2 CLTB
CXCL-12 IGF-1 LRP-1
CCL-11 MMP-3
CSF-1 PGM-1
CSF-2 CD44
IFNG MFGE-8
PA2G4
UBE2D3
NRP-2
IGFBP-1
AGT
MAPK
RUVBL-1
HSPD-1
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Avoiding immune destruction
The immune system plays a considerable role in tumor devel-
opment. Tumor progression and spread is sustained by the
immunoediting hypothesis in which the tumor environment is
selected for escape from the immune system (19). Major escape
mechanisms to anti-tumor immune response are induction of
regulatory T (Treg) cells or immunosuppressive molecules such
as programed cell death protein-1 or cytotoxic T-lymphocyte
(CTL)-associated protein-4 on CTLs and down-regulation of
antigen-presenting molecules (47). Treg cells are CD4+, CD25+,
Foxp3+ immunosuppressive lymphocytes that suppress autore-
active T-cells to maintain immunological self-tolerance and
inhibit autoimmunity (48). Treg cells secrete immunosuppres-
sive cytokines, as IL-10 and TGF-β, and metabolites such as
adenosine (47).
Effector cells responsible for the immune response in the tumor
stroma include on the one hand tumor-promoting regulatory den-
dritic cells (DCs), M2 macrophages, N2 neutrophils, myeloid DCs,
and Treg cells; and on the other hand, tumor-inhibiting classic
DCs, M1 macrophages, N1 neutrophils, CTLs, natural killer (NK)
cells, and natural killer T (NKT) cells (Table 2) (19, 47). Tumor
and CAF secretion of chemokines can recruit immunosuppres-
sive myeloid-derived suppressor cell population (MDSC) to the
tumor. MDSC comprise neutrophils, immature DCs, monocytes,
and early myeloid progenitors. They not only suppress adaptive
immunity, but also promote angiogenesis through the secretion
of VEGFA, bFGF, and TGF-β. MDSCs also inhibit NK cell func-
tion and enlarge the Treg cell population. In addition, MDSCs
can directly inhibit effector T (Teff , CD4
+, Foxp3−) cell growth,
activation, and migration by altering the environment (Table 2)
(49). Cells such as MDSC, Treg cells, and M2 tumor-associated
macrophages (TAMs) are recruited or differentiated in the tumor
microenvironment. These cells further enhance the helper T-cell-
2 polarization often synonym of CTL suppression and cancer cell
dissemination (17).
The regulation of the anti-tumor immune response by CAFs
has recently been reviewed by Harper and Sainson (17). To study
the role of CAFs from CRC in immune response, we used pre-
viously published data from our group to re-analyze proteins
secreted uniquely by CAFs and by the combination of CAFs and
recombinant TGF-β1-treated MSCs, which are not secreted by
non-treated MSCs (24). To reveal if some of these proteins were
related to immunity, we used FunRich (http://www.funrich.org/)
which gives the opportunity to cluster the secreted proteins by
biological processes or pathways. Approximately 1/5 of all secreted
proteins are implicated in immune system, immune response, or
Table 2 |Tumor-promoting versus tumor-inhibiting immune cells.
Tumor-promoting Tumor-inhibiting
CD4+, CD25+, Foxp3+ Treg cells CD8+ CTLs
MDSC NK cells
Regulatory DCs NKT cells
Myeloid DCs Classic DCs
M2 macrophages/monocytes M1 macrophages
N2 neutrophils N1 neutrophils
immune-related pathways, such as IFN-γ signaling and chemokine
response (Table 3).
In CRC development, the immune system plays a complex role.
Although chronic inflammation, including inflammatory bowel
disease, can be a precursor to CRC development, a distinct anti-
tumor CD3-positive T-cell response is the best predictor of long-
term survival for CRC patients. In CRC, a pronounced desmo-
plastic reaction is associated with a reduced immune response.
Therefore, CAFs may play a role in tumor immune evasion (3).
In corresponding tumor tissue sections from the same patients,
the amount of intercellular adhesion molecule (ICAM)-1-positive
CAFs was significantly higher than that in the corresponding
normal colon mucosa. These results indicate that CAFs from
CRC tissue exhibit an increased affinity for monocytic cells. This
increased intercellular interaction may contribute to extended res-
idence times of monocytes in CRC tissue (50). Co-expression of
CAF and M2 macrophage markers is associated with the clinical
outcome of CRC patients. TAMs can be present in the tumor
in two phenotypically different populations. M1 macrophages
will develop an anti-tumor response by producing inflamma-
tory molecules (IL-6, IL-12, IL-23, and TNF-α) and ROS, NO,
and TNF. M2 macrophages secrete immunosuppressive cytokines
(IL-10 and TGF-β) and promote tumor progression by stimu-
lating angiogenesis and degradation of the ECM (15, 47). M2
macrophages are CD163+ and correlate with CAF markers. Mul-
tivariate analysis demonstrates that the combination of both vari-
ables is an independent prognostic marker for poor disease-free
survival and overall survival and which is statistically stronger
than either of both alone (15). In agreement, CD163 immunohis-
tochemical staining on patient sections of primary colon tumors
revealed a high presence of TAM in zones with high presence
of α-SMA-positive CAFs (Figure 2). This suggests a correlated
expression pattern of both M2 macrophages and CAFs. CD8
immunohistochemical staining illustrated that T-lymphocytes are
widespread and infiltrate the cancer cells (Figure 2).
Table 3 | Immune-related proteins secreted uniquely by CAFs from
CRC and by the combination of CAFs and recombinantTGF-β1-treated
MSCs according to their category.
Chemokine response Interferon signaling Mixed immune system
CCL-5 CD44 CSF-2
CXCL-12 PPP2CA MAPK-1
CCL-11 PPP2R1A UBE2D3
CCL-7 GBP-1 CALR
CXCL-16 GBP-2 CD14
IFNG C3
ISG-15 PSMD-7
PSMD-3
PSMD-8
CXCL-6
CD59
CSF-1
CYTL-1
MR-1
HSPD-1
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FIGURE 2 | Photomicrographs showing hematoxylin and eosin staining (A) and immunohistochemical staining of α-SMA (B), CD8 (C), and CD163
(D) on consecutive sections of a primary colon tumor. Scale bar is 100µm. CC, cancer cells; S, stroma; BV, blood vessel; IC, immune cells.
Heterogeneity of the tumor immune context is influenced by
various factors, including those secreted by CAFs and the can-
cer cells themselves. For instance, microsatellite unstable CRCs
have a more intensive CTL infiltration and better prognosis than
microsatellite stable CRCs (47). On the other hand, IL-11, a TGF-β
target gene in CAFs, contributes to a survival advantage to metasta-
tic cells. IL-11 stimulates platelet production. Platelets protect
circulating cancer cells from immune attacks, as well as sup-
port them during extravasation. In addition, platelets are a rich
source of TGF-β (51). IL-6 and PGE-2 derived from colon CAFs
were identified as potential immune-suppressive molecules (14,
21, 29). In co-culture experiments, CAFs from CRC intensely sup-
pressed the expression of the NK receptors, perforin and granzyme
B, but they also inhibited the secretion of the cytokines TNF-
α and IFN-γ by NK cells. In the presence of NK cells, CAFs
produced pro-inflammatory lipid mediator PGE-2 at higher lev-
els than fibroblasts from healthy donors. These results suggest
that CAF-mediated secretion of PGE-2 is involved in regulating
the functionality of NK cells by suppressing their activity, which
promotes tumor growth (52).
Tumor-promoting inflammation
Inflammation is increasingly considered as a pivotal environmen-
tal factor contributing to tumor progression (13). Quantitative
proteomic analysis has been performed on supernatants of CAFs
isolated from an azoxymethane/dextran sodium sulfate mouse
model of sporadic colon cancer (29). Protein networks indi-
cated the association with desmoplastic and pro-inflammatory
signatures. Pro-inflammatory signature is composed of several
cytokines such as chemokine (C–C motif) ligand (CCL) 2
(MCP-1), CCL-8 (MCP-2), CCL-11 (Eotaxin-1), CCL-20, SAA-3,
chemokine CXCL-2, CXCL-3, CXCL-5 (ENA-78), CXCL-12 (SDF-
1), or CXCL-14. Furthermore, IL-6, IL-9, and osteopontin were
up-regulated, whereas CSF1 was down-regulated in CAFs (14, 21,
29). CCL-2 is a chemokine involved in attracting macrophages
into the tumor microenvironment and it also induces differen-
tiation into an immunosuppressive M2 phenotype (17). CCL-8
attracts monocytes and lymphocytes. Addition of CCL-2 and
CCL-8 to cultures of human CRC cells increased adhesion, migra-
tion, and invasion levels (29). CAF-derived chemokines CXCL-12
or CXCL-14 recruit bone marrow-derived cells, macrophages, and
other immune cells into the tumor microenvironment, enabling
tumor growth. Additionally, they recruit endothelial progenitor
cells into tumors (21). IL-9 induced an increase in the prolif-
eration of CRC cells (29), whereas IL-6 contributes to immune
cell dysfunction and is known as a regulator of CD4+ T-cell
differentiation (17). The expression of CCL-3 and its receptor
CCR-5 were increased in the azoxymethane/dextran sodium sul-
fate mouse model. The numbers and size of colon tumors were
lower in CCL-3- or CCR-5-deficient mice, in parallel with reduced
CAF accumulation. In vitro, CCL-3 stimulated fibroblast prolifera-
tion and enhanced heparin-binding epidermal growth factor-like
growth factor (HB-EGF) expression. These results indicate that
CCL-3–CCR-5-mediated fibroblast accumulation may be required
to induce colitis-associated carcinogenesis (53).
Cyclooxygenase (COX)-2, which is part of the pro-
inflammatory signature of CAFs (23), is overexpressed in the
majority of CRCs. COX-2-derived PGE-2 promotes tumor growth
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by inducing cancer cell proliferation, survival, migration/invasion,
and by enhancing the development of a supportive tumor
microenvironment. Additionally, PGE-2 suppresses effector T-
cells (21). Normal intestinal fibroblasts activate signal transducer
and activator of transcription 1 (STAT1) signaling in CRC cells
and in contrast to CAFs, inhibit growth of cancer cells. CAFs lose
the ability to trigger growth inhibitory STAT1 signaling in cancer
cells, favoring tumor progression and suggesting STAT1 as a link
between intestinal inflammation and CRC. PGE-2 has been shown
to interfere with STAT1 activity, and may therefore contribute to
the incapability of CAFs to activate STAT1 signaling in cancer cells
(23). Pro-inflammatory cytokine LIF is secreted by cancer cells
and fibroblasts treated with TGF-β1, which highlights the action
of TGF-β1 as a driver of tumor-associated inflammation (54).
Activating invasion and metastasis
Incubation of CAFs with supernatants from CRC cells leads to
hyperactivation of TGF-β signaling pathway. A strong autocrine
regulatory loop augments the expression and secretion of TGF-β1
by CAFs (22). Stromal TGF-β signaling promotes metastasis for-
mation (51). Two-thirds of mice bearing control KM12L4A colon
tumors remained metastasis-free, whereas 10 of 11 mice inocu-
lated with KM12L4A cells overexpressing TGF-β developed lung
and/or liver metastasis. Because KM12L4a cells have an inactivated
TGF-βpathway, enhanced metastasis initiation by TGF-β secretion
must be due to changes in the tumor environment. Secretion of
IL-11 by TGF-β stimulated CAFs triggers GP-130/STAT-3 signal-
ing in cancer cells. This crosstalk suggests a survival advantage for
metastatic cells. Metastasis initiation was blocked in mice treated
with a pharmacological inhibitor of TGF-βR1. Metastases derived
from TGF-β-secreting cell lines exhibited enhanced desmoplas-
tic reaction with abundant phospho-SMAD2 accumulation in
stromal cells and elevated expression of stromal TGF-β response
signatures genes (51). TGF-β is involved in tumor metastasis devel-
opment by increasing production of ECM and proteolytic enzymes
(22). CAFs are the main source for connective tissue components
of the ECM, such as collagens types I, III, IV,V, and XII, and proteo-
glycans (biglycan, fibromodulin, perlecan, and versican) (14, 29).
Treatment of CAFs with TGF-β1 in vitro increased the expression
of type I collagen, fibronectin, urokinase type plasminogen activa-
tor (u-PA), various MMPs (e.g., MMP-2 and MMP-9), and TIMPs
in CAFs (22). Similarly, genes induced in CAFs, compared to nor-
mal resting colonic fibroblasts, include several tumor-promoting
MMPs (MMP-2 and MMP-12) and ECM proteins implicated in
invasion and metastasis, such as tenascin-C and laminin-B1 (14).
The expression of MMPs in CAFs is generally high compared to
CRC cells (22, 29). One of the main components of the basement
membrane, type IV collagen, is a substrate of MMP-2 and MMP-
9. The role of MMPs is apparent to be essential in invasion and
metastasis (6, 22).
Snail1 expression was higher in colon CAFs than in nor-
mal fibroblasts. Snail1 is a transcriptional factor that plays an
important role in epithelial–mesenchymal transition and in the
achievement of invasive properties by epithelial cells. Co-culture
of CAFs with CRC cells induced an increase in CRC cell migra-
tion and proliferation, which was correlated with mRNA SNAI1
expression levels in primary human CAFs (55). In another study,
spheroids of CRC cells were co-cultured with CAFs in a colla-
gen invasion experiment. Investigation of the F-actin organization
revealed that spheroids in control conditions had smooth edges,
whereas the spheroids in co-culture had an irregular perime-
ter with individual and collective cells invading the surround-
ing collagen matrix (24). Similarly, treatment of CRC cells with
supernatants from CAFs induced a fivefold increase in a colla-
gen invasion assay (28). In accordance, HCT116 cells treated with
CAF supernatants showed a more elongated morphology com-
pared to cells growing in supernatants from resting fibroblasts.
CAFs increased the migration and invasion of CRC cells in Boy-
den chamber experiments and in a three-dimensional cell culture
model (4, 16). FGFR-3 was identified as one of the receptor tyro-
sine kinases activated by CAF supernatants. CAFs hypersecreted
FGF1 and increased FGF-1/FGFR-3 signaling led to migration
and invasion (16). Herrera et al. demonstrated a clear associa-
tion between the expression levels of α-SMA and promigratory
stimulation of CRC cells. Most promigratory CAFs showed stem-
cell markers. The association between typical stem-cell markers
of CAFs and their promigratory effect on cancer cells was also
demonstrated (4).
Elevated expression of PDGFRs on stromal CAFs is associ-
ated with advanced disease stage and an increased metastatic
potential (21, 56). PDGF-stimulated fibroblasts increased migra-
tion and invasion of co-cultured CRC cells in a stanniocalcin-1
(STC-1)-dependent manner. STC-1 is a hypoxia-regulated and
fibroblast-derived protein. In an orthotopic CRC model, there
was a difference in the number of affected organs such that the
tumors derived from the STC-1−/− group showed a significantly
lower number of affected organs per mouse. The foci were also
significantly smaller than those in the control group and a signifi-
cant decrease of lymphatic vessel density was observed in primary
tumors with STC1−/− mouse embryonic fibroblasts (56).
TGF-β1 stimulates the pro-invasive properties of human der-
mal fibroblasts by inducing LIF production. LIF-activated dermal
fibroblasts gain cellular contractility and provide ECM remodeling
via a crosstalk between the JAK1/STAT3 and RhoA/ROCK/MLC2
signaling pathways, reciprocally resulting in cancer cell invasion
in vitro and in vivo. It was demonstrated that α-SMA expression,
which depends on TGF-β signaling, is independent of LIF. Treat-
ment with anti-TGF-β antibody had no effect on pro-invasive
fibroblast activation, whereas LIF-blocking antibody completely
abolished the pro-invasive effects of supernatants of squamous cell
carcinoma. The latter activated STAT3 in fibroblasts only through
LIF secretion. This indicates that monitoring α-SMA expression is
not a criterion sufficient to reveal the presence of all the pro-
invasive CAFs, which thus may lead to a biased prognosis for
patients (54).
TUMOR-INHIBITING CHARACTERISTICS OF CAFs
Transgenic mice were generated with the ability to deplete
α-SMA+ myofibroblasts in pancreatic cancer. Ptf1acre/+; LSL-
KrasG12D/+; Tgfbr2flox/flox (PKT) mice, which develop sponta-
neous pancreas cancer, were crossed with α-SMA-tk transgenic
mice to selectively target proliferating α-SMA+ myofibroblasts
upon systemic ganciclovir administration. Depletion of CAFs
led to invasive, undifferentiated tumors with enhanced hypoxia,
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EMT, and cancer stem cells, with reduced animal survival. Sim-
ilarly, in pancreatic ductal adenocarcinoma patients, fewer CAFs
also correlated with reduced survival. CAF depletion was asso-
ciated with an overall decrease in the Teff/Treg ratio associated
with increased CTL-associated protein-4 expression. If CAFs are
depleted, the tumor vasculature decreases, which may directly con-
tribute to increased tumor hypoxia. Consequently, this promotes
enhanced invasiveness and an undifferentiated phenotype of can-
cer cells. Thus, fibrosis associated with CAFs constitutes a protec-
tive response from the host rather than supporting an oncogenic
role in pancreatic ductal adenocarcinoma patients (57). CAFs sur-
rounding CRC cells demonstrated up-regulation of podoplanin,
a mucin-type transmembrane glycoprotein, in CAFs in vitro and
in vivo. Multivariate analysis of both disease-free survival and liver
metastasis-free survival revealed that podoplanin expression is a
significant indicator of good prognosis in patients with advanced
CRC. Moreover, CRC cell invasion was enhanced by co-culture
with CAFs that were treated with siRNA for podoplanin, sug-
gesting a protective role against CRC cell invasion (58). However,
reports about tumor-inhibiting characteristics of CAFs in CRC are
scarce.
FIBROBLASTS IN METASTASIS OF CRC
We distinguish CAFs from the primary tumor and metastasis-
associated fibroblasts (MAFs) in lymph node and distant metas-
tases of CRC (mainly liver and lung). Here, the focus is put on
liver metastases. MAFs may have other origins than CAFs and may
exhibit other properties to prepare or maintain the (pre)metastatic
niche.
Metastatic deposits of CRC within the liver are also charac-
terized by a pronounced desmoplastic reaction associated with
α-SMA+ MAFs (Figure 3) (59). HSCs are recognized as a major
source of MAFs (59, 60). In mice experiments, HSCs were acti-
vated by various stimuli, e.g., PDGF-AB, HGF, and TGF-β and
underwent transformation into MAFs when CRC cells migrated
into the liver (59). Additional cell types such as resident liver
fibroblasts/myofibroblasts or bone marrow cells are also known to
generate MAFs (13, 60). Portal fibroblasts are present around the
portal vein and fibroblastic cells around the central vein are called
second-layered cells. The liver surface is covered with mesothe-
lium, which is composed of mesothelial cells and fibroblastic cells
called capsular fibroblasts. These fibroblastic cells around the veins
and beneath the mesothelial cells have been suggested to differen-
tiate into MAFs. Portal fibroblasts proliferate and differentiate into
α-SMA-expressing MAFs and synthesize ECM proteins, similar to
activated HSCs. Interestingly, unlike activated HSCs, portal fibrob-
lasts do not respond to PDGF and their growth is rather inhibited
by TGF-β (60).
Liver metastasis produces cancer-associated stroma organized
into strands of α-SMA+ MAFs. Strands of MAFs are infiltrated
by CD8 T-lymphocytes and CD163-activated macrophages. A dis-
crete pattern of hepatocytes is massively surrounded by stroma and
CRC metastatic cells (Figure 3). A comparative analysis between
each primary tumor and a corresponding metastatic lesion showed
that both displayed similar α-SMA values (18). However, in dis-
tant metastases of CRC those from the lung had fewer MAFs than
those from the liver, peritoneum, or ovary. CRC cases with higher
CAFs in center of the primary cancers had a tendency of higher
FIGURE 3 | Photomicrographs showing consecutive sections of liver metastasis of a CRC patient stained by hematoxylin and eosin (A) and stained
immunohistochemically for α-SMA (B), CD8 (C), and CD163 (D). Scale bar is 100µm. CC, cancer cells; IC, immune cells; S, stroma; H, hepatocytes.
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MAFs in periphery (61). Desmoplastic reaction promotes growth
and chemoresistance of CRC liver metastases (3).
Comparison of MAFs from liver metastasis of CRC with skin
fibroblasts revealed up-regulation of genes of adhesion molecules,
ECM/ECM remodeling molecules, proteases/protease inhibitors,
and several growth factors and survival cytokines, including
PDGFA, FGF-1, IGFBP-7, IGFBP-5, CTGF, prostate differenti-
ation factor, VEGF, TGF-β2, monocyte chemotactic protein-1
(MCP-1), IL-6, osteoprotegerin, follistatin, follistatin-related gene,
COX-2, and TGF-β (20). Supernatants from MAFs from liver
metastasis of CRC enhanced proliferation of HCT116 CRC cells,
more than supernatant from uninvolved skin fibroblasts. How-
ever, in comparison to liver fibroblasts, the results were not sig-
nificant, and no data are available where MAFs are compared
with CAFs (20). The colorectal metastases display immunore-
activity for TNF-α in cancer cells, whereas stromal fibrob-
lasts are negative. Increased migration of CRC cells induced
by TNF-α-treated MAFs from human liver metastases has been
demonstrated. These TNF-α-treated MAFs showed an increased
expression of IL-6, MCP-1, and ICAM-1 (62). In liver metas-
tasis, periostin immunoreactivity was observed in the capsu-
lar stroma. Whereas there was little periostin immunoreactivity
in normal liver tissue, including the portal areas. As described
previously, periostin promotes growth and colony size of CRC
cells (12).
In liver metastases from CRC, α-SMA+ MAFs derived from
HSCs, surrounding the liver metastasis foci, secrete SDF-1.
Immunohistochemistry was performed to examine the expres-
sion of CXCR4, the receptor of SDF-1 ligand, in human samples
of CRC and liver metastasis. It was shown that the proportion of
CXCR4 expression in the primary tumors with liver metastasis
was higher than in those without liver metastasis. Moreover, there
are more CXCR4+ cells at the metastatic site in the liver compared
with the primary sites. Stimulation with SDF-1 increased the num-
ber of invading HCT116 cells in vitro. Additionally, HCT116 cells
became resistant to apoptosis by SDF-1 stimulation. This phe-
nomenon suggests that liver metastases could be formed with the
help of MAFs secreting SDF-1. CRC cells may drift to the liver,
where MAFs secrete SDF-1 and promote tumor formation (59).
SDF-1 and CXCR4 expression were also significantly associated
with lymph node metastasis, tumor stage, and survival of CRC
patients. Most of the CRCs with lymph node metastases showed
strong SDF-1α expression, not only in the primary lesion but also
in their lymph node metastases (63).
During metastatic colonization, cancer cells may instruct the
stroma of the host organ by either secreting TGF-β or recruiting
TGF-β-producing cells such as macrophages, CAFs, or platelets.
IL-11 was among the genes highly up-regulated by TGF-β in
colon fibroblast cultures and in experimental metastasis gen-
erated from TGF-β-secreting KM12L4a cells. CAFs were the
only source of IL-11 in tumors. IL-11 enhances metastasis ini-
tiation and in this way the liver metastatic potential of CRC
cells. This involves STAT3 signaling in CRC cells, which sup-
presses apoptotic stimuli encountered during the colonization
of the metastatic site. Nuclear phospho-STAT3 accumulation in
primary CRC samples associates to advanced disease and poor
outcome (51).
CONCLUSION AND FUTURE PERSPECTIVES
The importance of CAFs in cancer progression through multi-
ple interactions with cancer cells and other cells in the tumor
environment suggests the use of CAF markers as prognostic
biomarkers. CAFs and their products should be considered as
novel therapeutic targets in primary and metastatic disease.
The abundance of α-SMA-expressing CAFs in CRC is sug-
gested as a useful indicator of poor prognosis. However, these
results were restricted to stage II and III CRCs (18). In patients
with advanced metastatic disease, increased stromal FAP is an
adverse prognostic marker (64). A significant correlation was
observed between stromal FAP-α and SDF-1 mRNA levels, pri-
marily expressed by CAFs, after pre-operative chemoradiother-
apy in rectal cancer patients (65). Positive gene expressions of
FAP-α and SDF-1 were significantly correlated with distant recur-
rence and poor probability of recurrence-free and overall sur-
vival. Patients with elevated serum SDF-1 levels had equally
poor overall survival as those with positive stromal SDF-1 gene
expression (65). In CRC patients, the combination of calu-
menin with cadherin 11 expressed by CAFs displayed a signif-
icant association with disease-free survival and overall survival
(29). In conclusion, detection and monitoring of CAF reac-
tions may better define prognosis. Future research will determine
if CAFs are potential target candidates in cancer management
protocols.
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